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Abstract
Background: Linezolid is the first synthetic compound of
a new group of antimicrobials, the oxazolidinones, which
inhibit protein synthesis. It shows a broad spectrum of activ-
ity against Gram positive organisms. With respect to its phar-
macokinetics, linezolid shows a relatively high volume of
distribution and good penetration into inflammatory fluids,
bone, fat and muscle.
Methods: A reversed-phase isocratic high-performance liq-
uid chromatographic method for linezolid analysis in piglet
pulmonary tissue is described. Tissue samples and controls
were prepared in 1=TBE (1 M Tris, 0.9 M boric acid, 0.01
M EDTA). The mobile phase consisted of 20% ultrafiltered
water and 80% of (A) 15 mM potassium monohydrogen
phosphate buffer (pHs5) with (B) acetonitrile (80%/20%;
v/v). Samples were homogenized and precipitated with
HClO4 3% (1/1, v/v). The injection volume was 100 mL.
Ofloxacin was used as an internal standard.
Results: The assay was linear over a linezolid concentration
range: 1.6–100 mg/mL. The method provided good valida-
tion data (ns15): inaccuracy (3.6%), intra and inter-day var-
iability (4.2% and 5.2%, respectively), recovery (91.8%),
limit of detection (0.8 mg/mL) and quantitation (1.6 mg/mL)
and acceptable stability within 24 h in the auto-sampler.
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Conclusions: The method offers a fast and simple approach
to determine linezolid in pulmonary tissue which could be
of use in pharmacokinetic studies.
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Introduction
Linezolid (LNZ) (1) is the first synthetic compound of a new
group of antimicrobial drugs, the oxazolidinones (Figure 1)
which inhibit protein synthesis early in translation. It shows
a broad spectrum of activity against Gram positive organ-
isms including methicillin resistant Staphylococcus aureus
(MRSA), penicillin resistant pneumococci and vancomycin
resistant Enterococcus faecalis and Enterococcus faecium.
After a dose of 600 mg twice a day, the maximum serum
concentration is ;20 mg/L. With respect to its pharmaco-
kinetics (PK), linezolid shows a relatively high volume of
distribution (40–50 L) and good penetration into inflamma-
tory fluids, bone, fat and muscle (2).
It is well known that antibiotic concentrations at the site
of the infection differ greatly from those in plasma. Drug
penetration varies depending on the drug, the tissue involved
and the infection. Also, protein binding, physical-chemical
drug properties, lipid solubility, etc. have some influence on
the amount of drug that is able to reach peripheral tissue/
compartments. Data on drug penetration for the latest
antimicrobial drugs, such as ertapenem, tigecycline, teli-
thromycin or linezolid have recently been published (3–6).
Thus, in localized infections including lung infection, men-
ingitis, endocarditis or osteomyelitis, it is extremely valuable
to know what fraction of the free drug will be able to cross
membranes and barriers and reach the site of the infection.
Hence, many reports in the literature have been performed
on drug penetration into different tissues. Examples include
drug penetration into the epithelial lining fluid (ELF) (7–10)
and lung tissue (11).
High performance liquid chromatography (HPLC) can be
considered an adequate technique (12) for determining line-
zolid in pulmonary tissue. The sensitivity and precision of
HPLC and its applicability to a wide variety of compounds
has led to its use in clinical laboratories for monitoring of a
variety of therapeutic agents in hospital settings, and phar-
macokinetic and metabolism studies (13, 14).
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Figure 1 Chemical structure of linezolid.
The goal of this study was to develop a new assay to
quantify linezolid in lung tissue obtained from a model of




Linezolid and ofloxacin, the internal standard (IS), were obtained
from Pfizer, S.A. (Madrid, Spain) and Riedel-deHaën Sigma-
Aldrich Laborchemikalien GmbH (Seelze, Germany), respectively.
Perchloric acid 70% PRS and potassium phosphate dibasic, ACS
reagent, G98% were purchased from Panreac (Barcelona, Spain)
and Sigma-Aldrich (Steinheim, Germany). Acetonitrile gradient
240/far-UV-HPLC grade was acquired from Sharlau, S.A. (Barce-
lona, Spain) and the 10=TBE Buffer Ultrapure (1 M Tris, 0.9 M
boric acid, 0.01 M EDTA) from Invitrogen (Paisley, Scotland).
Instrumentation
HPLC was performed using an Agilent 1100 liquid chromatography
system (Agilent Technologies Spain, S.L., Madrid, Spain) consisting
of a vacuum degasser, a gradient pump, an auto sampler and vari-
able wavelength ultraviolet (UV) detector. Data acquisition was per-
formed using the appropriate software (Agilent Chemstation
Rev.B.03.01) for signal treatment.
High-performance liquid chromatography
The HPLC method used in this study is based on the method pro-
posed by Tobin et al. to determine linezolid in plasma (15).
In the present study, the stationary phase was a silica based col-
umn Novapak C18 (150=3.9 mm) with pre-column from Waters
Corporation (Milford, MA, USA). The mobile phase consisted of
20% ultrafiltered water and 80% of (A) 15 mM potassium mono-
hydrogen phosphate buffer (pHs5) with (B) acetonitrile (80%/20%;
v/v). The flow rate was fixed to 0.7 mL/min and the injection vol-
ume to 100 mL. UV absorbance detection was set at 254 nm.
Drug analysis and calibration
Calibration curves were constructed by cutting small pieces of con-
trol lung tissue (from pigs without antibiotic treatment). The
observed peak-area ratio method with reference to the IS was
applied to assess drug concentration.
Calculation of the unknown linezolid concentration in tissue sam-
ples was performed using the linear regression equation of the peak
area ratio against the concentration ratio for the calibration curve.
Correction for the tissue experimental weight was taken into
account. A standard equation to normalize weights of pulmonary
tissues and the extracted volume after the homogenization process
was used Eq. w1x (16).
(((A /A )/g )=V )snqm=w((LNZ )/(Oflox ))LNZ Oflox exp Real theor theor
=(g /g )=V x w1xexp theor Real
where: ALNZ: linezolid area (mAu); AOflox: ofloxacin area (mAu);
wLNZtheorx: linezolid theoretical concentration (mg/mL); wOfloxtheorx:
ofloxacin theoretical concentration (mg/mL); gexp: pulmonary pig
tissue experimental weight (g); gtheor: pulmonary pig tissue theoret-
ical weight (0.5 g); VReal: real volume (L); m: slope; n: ordinate at
linezolid concentrations equals 0.
Sample collection
Samples were obtained from a model of pneumonia, developed in
mechanically ventilated piglets that were treated with linezolid. All
tissue samples (standards, quality controls and experimental) were
freshly cut into pieces of ;0.5 g, and kept frozen at –408C until
analysis. Prior to analysis, they were homogenized in a manual
homogenator supplied by ANORSA (Barcelona, Spain).
Preparation of standard and quality controls
Buffer solution (1$TBE buffer) A 1=TBE buffer solution was
prepared by dilution of 10=TBE (1 M Tris, 0.9 M boric acid,
0.01 M EDTA) in ultrapure water (1/10). This solution was main-
tained at room temperature.
Stock standard and quality control solutions The same stock
solution containing 2 mg/mL of linezolid was used to prepare both
standard and quality control material. From this stock solution, three
levels of quality control (working standard solutions) at 3.1 mg/mL,
25 mg/mL and 100 mg/mL of linezolid were prepared by appropri-
ate dilutions in 1=TBE. These dilutions were spiked with ofloxacin
to achieve a final concentration of 100 mg/mL.
Standard preparation Tissue control specimens (0.5 g) were
spiked with the appropriate volume of a stock linezolid solution to
attain several standard samples of different linezolid concentrations,
and with 70 mL of ofloxacin standard solution (500 mg/mL). Final-
ly, 262.5 mL of 1=TBE was added to obtain a final volume of
350 mL for standards, quality control and unknown samples. These
standards were homogenized for 30 s and then extracted and pre-
cipitated with 350 mL of HClO4 3% (1/1, v/v). Next, they were
centrifuged at 8000=g for 10 min. Finally, 100 mL of the super-
natant was injected into the chromatographic system.
Sample preparation All tissue samples (0.5 g) were added with
350 mL of 1=TBE spiked with the IS at 100 mg/L. These speci-
mens were homogenized for 30 s, extracted and precipitated with
350 mL of HClO4 3% (1/1, v/v). Afterwards, they were centrifuged
at 8000=g for 10 min and 100 mL of the supernatant was injected
into the chromatographic system.
Validation criteria
In accordance with the USA Food and Drug Administration’s Guid-
ance for Industry Bioanalytical Method Validation, and the Euro-
pean Agency for the evaluation of Medicinal Products’ Guideline
on Validation of Analytical Procedures, the following seven criteria
were evaluated: linearity, accuracy, precision, recovery, limits of
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detection and quantitation and stability (17–21). In addition, in this
study, quality control samples were analyzed in parallel to establish
the suitability of the method.
Linearity Calibration curves were constructed by cutting small
pieces of control lung tissue (from pigs without antibiotic treat-
ment). A seven-point standard curve of linezolid was constructed
by drawing the ratio between the peak area of linezolid and the
peak area of ofloxacin vs. the ratio between linezolid concentration
and ofloxacin concentration. The concentration of linezolid ranged
from 1.6 to 100 mg/mL.
Calculation of the unknown linezolid concentration in tissue sam-
ples was performed using the linear regression equation of the peak
area ratio against the concentration ratio for the calibration curve.
Correction for the tissue experimental weight was taken into
account. A standard equation to normalize the weights of pulmonary
tissues and the extracted volume after the homogenization process
was used Eq. w1x (16).
Linearity was assessed using Pearson’s coefficient (r), the coef-
ficient of correlation (r2), and the (tstudent) for the slope and Pearson’s
coefficient.
Accuracy and precision Accuracy of an analytical method is
defined as the agreement between results obtained by the analytical
method to the true value. Precision describes the degree of the sim-
ilarity (17). The accuracy of the method was performed using a
recovery study with 15 drug-spiked samples at three concentrations
(100, 25 and 3.1 mg/mL) measured in one run performed in a single
day. This allowed us to determine intra-day precision and accuracy.
Analysis of the same drug concentrations over three consecutive
days was performed to determine inter-day precision. Accuracy and
precision were calculated as follow Eqs. w2, 3x, respectively:
%E s(wLNZx –wLNZ x)/wLNZ x=100 w2xR exp theor theor
where: ER: accuracy; wLNZtheorx: linezolid theoretical concentration
(mg/mL); wLNZexpx: linezolid experimental concentration (mg/mL).
%CVs(SD/X )=100 w3xave
where: CV: coefficient of variation; SD: standard deviation; Xave:
average concentration of drug (mg/mL).
For the analysis to be considered acceptable, no more than one-
third of the quality control tests were allowed to deviate from the
nominal concentration by more than 15%, and at least 50% of the
results from each quality control sample had to be within 15% of
the nominal concentration.
Recovery Recovery was determined by comparison of the anal-
ysis between samples with known concentrations of the analyte and
extracts, obtained after homogenization of a piece of control pul-
monary tissue, spiked with linezolid (plus the IS) at the same con-
centrations as those prepared in the quality controls. Recovery was
calculated as follows:
R(%)s(A /A )/(A /A )=100 w4xLNZ Exp Oflox Exp LNZ Cont Oflox Cont
where: ALNZ Exp: linezolid area of the spiked extract (mAu);
AOflox Exp: ofloxacin area of the spiked extract (mAu); ALNZ Cont:
linezolid area of the control (mAu); AOflox Cont: ofloxacin area of the
control (mAu).
Limit of detection (LOD) Several samples with known concen-
trations of linezolid (plus the IS) were prepared fresh. The LOD was
established by visual evaluation of the minimum concentration at
which the linezolid signal can be reliably detected.
Lower limit of quantitation (LLOQ) The LLOQ is the lowest
amount of analyte in a sample which can be determined with pre-
cision and accuracy that is not -"20%. This parameter was estab-
lished by analysis of seven samples with known concentrations of
linezolid (linearity assay). Bias (ER%) and precision (%CV) at the
LLOQ were evaluated by a recovery study of five replicates.
Freeze and thaw stability Linezolid stability was determined
after three freeze (–408C) and thaw cycles of three drug-spiked
samples with concentrations of 100 mg/mL, 25 mg/mL, and 3.1
mg/mL, all measured in one run performed in 1 day.
Post-preparative stability The stability of processed samples at
room temperature, including the resident time in the auto-sampler
was determined using three aliquots with different concentrations.
We compared the results obtained with fresh sample with those
obtained with these same samples after 24 h (or real work time) in
the auto-sampler.
The non-parametric Wilcoxon test was used to compare results
and p-0.05 was used for statistical significance. Statistical analysis
was performed with SPSS 15.0 for Windows (SPSS Inc., Chicago,
IL, USA).
Pig pulmonary tissue samples
Lung tissue samples from a piglet model of pneumonia (22) were
analyzed in order to determine linezolid concentrations. Animals
were treated with 10 mg/kg (mean dose: 350 mg/12 h) of linezolid
twice daily (1) for 96 h, or until death. At euthanasia (at least 12 h
after the last dose of linezolid), pulmonary tissue was obtained from
several lung segments and kept frozen at –408C until analysis. Tis-
sue specimens (0.5 g) were spiked with 70 mL of ofloxacin standard
solution (500 mg/mL). Finally, 280 mL of 1=TBE was added to
obtain a final volume of 350 mL for all samples. These samples
were homogenized for 30 s, extracted and precipitated with 350 mL
of HClO4 3% (1/1, v/v). Afterwards, samples were centrifuged at
8000=g for 10 min. Finally, 100 mL of the supernatant was injected
into the chromatographic system.
Results
HPLC assay
Linezolid and the IS were quantitatively extracted from pul-
monary tissue after homogenation and precipitation. Under
the experimental conditions described in the previous section
(Materials and methods: High-performance liquid chromato-
graphy), linezolid and the IS were eluted within the retention
windows of 11–12 min and 5–6 min, respectively. Repre-
sentative chromatograms of blank tissue and quality control
samples are shown in Figure 2A, B.
Assay validation
The correlation between drug concentration and peak area
was excellent for TBE in tissue across the concentration
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Figure 2 Chromatogram of (A) blank lung tissue and (B) spiked control linezolid tissue (50 mg/mL).
Table 1 Results for validation parameters.
Linezolid 3.1 mg/mL 25 mg/mL 100 mg/mL
Intra-day inaccuracy (ER%) (ns5) –5.1 –7.5 2.1
Inter-day inaccuracy (ER%) (ns15) –4.8 –9.7 3.7
Intra-day precision (CV%) (ns15) 5.1 4.8 2.5
Inter-day precision (CV%) (ns15) 6.6 6.2 2.8
range studied (from 1.6 mg/mL to 100 mg/mL). Pearson
coefficient (r) and coefficient of correlation (r2) were cal-
culated: rs0.9978 and r2s0.9958. The regression line
(ys0.0052q2.4395x) was not significantly different from
the unity line (p)0.05). Inaccuracy, precision and recovery
were assessed by analyzing quality control samples. Results
are shown in Table 1.
The LOD was 0.8 mg/mL. The LLOQ was 1.6 mg/mL
(bias and precision: ER%s–7.6% and CV%s7.8%, respec-
tively). Typical chromatograms of the LLOQ are shown in
Figure 3A, B.
The mean recovery, calculated from the ratio of the areas
between linezolid and the IS (A.LNZ/A.Oflox), remained
fairly constant (93.6%, 92.5% and 89.5%) at three different
concentrations of linezolid (100, 25 and 3.1 mg/mL, respec-
tively). This confirms the use of ofloxacin as an IS.
Results from the stability analysis revealed no loss of line-
zolid after three freeze (–408C) and thaw cycles. Results are
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Figure 3 Chromatogram of (A) lower limit of quantification (LLOQ) including a zoom of the region of interest (B).
shown in Table 2. The IS (ofloxacin) showed degradation
after 3 h at room temperature. Thus, quantification (ALNZ/
AOflox) was not possible (Table 3). However, no significant
differences were seen in the linezolid signal (ALNZ) after
maintaining linezolid samples at room temperature for 24 h:
(ALNZ)0 hs10,331 mAu vs. (ALNZ)24 hs9910 mAu at 100
mg/mL; (ALNZ)0 hs1623 mAu vs. (ALNZ)24 hs1538 mAu at
25 mg/mL and (ALNZ)0 hs225 mAu vs. (ALNZ)24 hs198
mAu at 3.1 mg/mL.
Pig pulmonary tissue samples
Lung samples (from eight piglets treated with linezolid for
72–96 h) and controls (pulmonary tissues from piglets with-
out treatment) were collected. One sample was obtained 72 h
after starting treatment with linezolid (spontaneous death)
and 12 h from the last dose. All others were collected at
euthanasia after 96 h of treatment, and 12 h after the last
drug dose. All were cut in pieces of ;0.5 g and immediately
frozen at –408C until analysis.
Mean ("standard deviation) minimum linezolid concen-
trations in lung tissue (ns8) were 11.0"5.1 mg/L.
Discussion
A specific HPLC method with adequate specificity, sensitiv-
ity, precision and accuracy has been developed to measure
linezolid in lung tissue. This method allows rapid determi-
nation of linezolid concentrations in pulmonary tissue, offer-
ing a highly simplistic approach to sample preparation. It is
accurate, reproducible and specific for linezolid.
Several examples of extraction and quantitation of anti-
biotics in different tissues have been described in the liter-
ature. The majority of them are based on homogenization
using a homogenator or sonication system as the best tech-
nique to extract the drug from the tissue (23–26). After-
wards, samples are centrifuged, washed by filter or solid
phase extraction (SPE), evaporated and re-diluted in an
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Table 2 Results from the stability analysis of linezolid in lung
tissue after three freeze (–408C) and thaw cycles.
Linezolid ALNZ/AOflox ALNZ/AOflox p-Value
at baseline after 3 cycles
100 mg/mL 2.18 2.17 0.29
25 mg/mL 0.37 0.38 0.18
3.1 mg/mL 0.05 0.05 0.56
ALNZ/AOflox, linezolid area/ofloxacin area; p-0.05 to be significant.












aNA, not available. (Double peak).
appropriate mobile phase. With respect to linezolid, there are
several HPLC methods that have been published in the lit-
erature for measuring this drug in serum or plasma (15,
27–30). However, there are only a few HPLC methods for
measuring linezolid quantification in tissues. One is the pro-
cedure described by De Jesús et al. (31). They propose an
HPLC technique in which 1 g of pulmonary tissue is homog-
enized in a buffer solution w(KH2PO4, Na2HPO4Ø12H2O)/
0.1% Triton x-100 (pH 7.4)x, centrifuged, and 100 mL of
supernatant is injected into the chromatographic system. In
this method, the column temperature is maintained at 288C
under isocratic conditions. The quantitation limit is 0.25 mg/
L and imprecision is -10%. It is noteworthy to consider
that these data are similar to our results given that, in our
study, the LOD and LLOQ are 0.8 mg/mL and 1.56 mg/mL,
respectively. Also, the intra-day and inter-day precision is
-6.5% across the entire range of concentrations studied.
Our data are consistent with the results reported by Honey-
bourne et al. (11). They analyzed linezolid in several tissues
including bone, fat and muscle, but not lung, by homogeniz-
ing the tissue with acetonitrile. Afterwards, these samples
were centrifuged and the supernatant injected into the chro-
matographic system. The LLOQ is set at 0.1 mg/L and the
intra-day and inter-day coefficient of variation was -6.0%
and 12.5%, respectively. Our study using pulmonary tissue
shows much better results than those reported previously. In
our study, intra-day precision (five replicates at three differ-
ent concentrations) is -5.5% in all cases, and the inter-day
precision (five replicates analyzed in three consecutive days)
is -6.5%. In our study, the LLOQ was no -1.56 mg/mL.
However, it should not have any impact in terms of clinical
significance since this value is below the minimum inhibitory
concentration of linezolid for MRSA.
Moreover, data from another study (32) which treated lung
samples with a mixture of methanol/water (1:1) and lysing
buffer, showed results similar to ours with respect to recov-
ery values: 96% and 103% vs. 89.47% and 93.58% in our
study.
Our data show lower minimum linezolid concentrations in
pulmonary samples than those reported by Luna et al. (33).
However, the lack of details on the methodology used to
determine linezolid concentrations in pulmonary tissue in
their study, and the fact that they used a different dose reg-
imen (300 mg/8 h), makes it very difficult to compare both
studies.
A possible limitation of the present study could be the
clinical interpretation of the drug concentrations in homo-
genates related to antibiotic levels at the site of infection.
Linezolid shows a low binding protein (31%), and good pen-
etration into skin, blister fluids, bone, muscle, fat, alveolar
cells, lung extracellular lining fluid and cerebrospinal fluid
(2, 34). It is well known that concentrations in tissue may
depend on (i) the amount of blood in the tissue sample,
(ii) chemical degradation of the drug during processing and
(iii) sample collection. Blood present in the tissue or in its
surface is included in the final homogenate. In order to
reduce possible bias due to this fact, an adjustment by weight
of the real analyzed portion of lung and the extracted volume
after homogenation were both taken into account in this anal-
ysis. With respect to chemical degradation, calibration with
IS (ofloxacin) was used to control any loss of specimen dur-
ing the analysis. In addition to circumvent any artifact or
loss of the drug during sample preparation, all standards were
prepared in the appropriate tissue homogenate (lung homo-
genate). To avoid the drawback related to sample collection,
all tissue samples were taken when the distribution phase of
the drug had been completed and equilibrium between the
vascular space and tissue was complete.
Homogenization implies disruption of cell membranes and
mixing of both intracellular and extracellular fluids and sol-
ids. However, in this particular case a minor dilutional effect
on linezolid concentration could be expected after tissue
homogenization since the drug is distributed primarily in the
extracellular space. However, one may hypothesize that line-
zolid concentrations in the biophase might be slightly higher
than those observed following tissue homogenization.
The availability of an HPLC method to determine antibi-
otic concentrations, both in serum and lung, provides a
unique opportunity to gain insight into relevant aspects
regarding the clinical response to specific treatments. Studies
in animal models of pneumonia, where it is possible to obtain
lung tissue, offer an exceptional opportunity to learn about
the pharmacokinetics and pharmacodynamics (PD) of anti-
biotics. The combination of PK and PD data might help to
further implement optimal antibiotic dosing regimens in
humans.
In conclusion, the HPLC assay we developed and reported
in this study allows for fast, easy, reliable and cheap analysis
of linezolid in pulmonary tissue. Linezolid analysis, per-
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formed using an isocratic mode, is completed within 12 min.
This method might be helpful to develop future pharmaco-
kinetic studies of linezolid penetration in pulmonary tissue.
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and rapid fully automated method for determination of tazo-
bactam and piperacillin in fatty tissue and serum by column-
switching liquid chromatography. J Chromatogra B 2002;
775:127–32.
24. Lifschitz A, Virkel G, Imperiale F, Sutra JF, Galtier P, Lanusse
C, et al. Moxidectin in cattle: correlation between plasma and
target tissues disposition. J Vet Pharmacol Therap 1999;22:
266–73.
25. Alvinerie M, Sutra JF, Capela D, Galtier P, Fernandez-Suarez
A, Horne E, et al. Matrix solid-phase dispersion technique for
the determination of moxidectin in bovine tissues. M Analyst
1996;121:1469–72.
26. Nave R, Fisher R, McCracken N. In vitro metabolism of beclo-
methasone dipropionate, budesonide, ciclesonide, and flutica-
sone propionate in human lung precision-cut tissue slices.
Respir Res 2007;8:65–74.
27. Ehrlich M, Trittler R, Daschner FD, Kümmerer KJ. A new and
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